ArticleImmunity2020
Plasmacytoid Dendritic Cells and Type I Interferon Promote Extrafollicular B Cell Responses to Extracellular Self-DNA.
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers.
0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 179 citations in OpenAlex.
- Vitamin D3 and deconvoluting a rash.JCI insight · 2023Trial
- Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.JAMA network open · 2022Trial
- InterferonFrontiers in immunology · 2020Trial
- Viral subversion of B-cell tolerance: mechanisms linking infection to autoimmunity.EMBO reports · 2026Review
- The SLC15A4-TASL complex is essential for lupus development in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Dysbiosis-induced expansion of AXL-positive inflammatory type 3 dendritic cells triggers preclinical autoimmunity.Nature immunology · 2026Article
- A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial.Nature medicine · 2026Article
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Molecular biomedicine · 2026Review
- TLR7 in systemic lupus erythematosus: genetics and emerging therapies.Nature reviews. Rheumatology · 2026Review
- Role of IFIT1 and IFIT3 in systemic lupus erythematosus: modeling a diagnosis and exploring immune regulation.Clinical and experimental medicine · 2026Article
- Autoreactive B cells in systemic lupus erythematosus: insights from integrative multi-omics analyses.Inflammation and regeneration · 2026Review
- Age- and tissue-dependent diversity of human plasmacytoid dendritic cells uncovers a cycling subset dominant in early life and cancer.Immunity · 2026Article
- B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts.Immunological reviews · 2026Review
- Germinal-centre and extrafollicular B cell pathways in systemic lupus erythematosus.Nature reviews. Rheumatology · 2026Review
- Jieduquyuziyin prescription for systemic lupus erythematosus: a system-level therapeutic strategy for immunological recalibration.Chinese medicine · 2026Review
- Childhood-onset hypocomplementaemic urticarial vasculitis in France: phenotypic and genotypic diversity in 10 children.Pediatric rheumatology online journal · 2026Article
- Upregulated ZBP1 Is Associated with B-Cell Dysregulation in Systemic Lupus Erythematosus.Biomedicines · 2026Article
- Novel perspectives on extracellular vesicles in autoimmune diseases: immunogenicity, inflammation, and immune surveillance.The Journal of clinical investigation · 2026Review
- Oleic acid alleviates the pathogenesis of lupus by suppressing the activation of TLR signaling pathways through the STAT3/IL-10 axis.Scientific reports · 2026Article
- TLR7 and TLR9 have overlapping but distinct roles in systemic lupus erythematosus and Sjögren's disease.Frontiers in immunology · 2026Review
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Chetna SoniDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Oriana A PerezDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
William N VossDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
Joseph N PucellaDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Lee SerpasDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Justin MehlDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Krystal L ChingDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Jule GoikeDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
George GeorgiouDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA; Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
Gregory C IppolitoDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA; Department of Oncology, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA.
Vanja SisirakCNRS-UMR 5164, ImmunoConcEpt, Université de Bordeaux, 33076 Bordeaux, France. Electronic address: vsisirak@immuconcept.org.
Boris ReizisDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA. Electronic address: boris.reizis@nyulangone.org.
New York University · USThe University of Texas at Austin · USCentre National de la Recherche Scientifique · FR
Funding
TRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3MTranslational Center of Molecular Profiling in Preclinical and Established Lupus (COMPEL)P50AR070591 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BUYON, JILL P · 2017 to 2021
$6.7MMolecular Control of Plasmacytoid Dendritic Cell Development and FunctionR37AI072571 · NIAID · UNIVERSITY OF CHICAGO · PI Boris Reizis · 2018 to 2026
$5.3MTraining Program in Immunology and Inflammation.T32AI100853 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Susan Ruth Schwab · 2012 to 2026
$4.5MMechanisms of DNA-Specific Autoimmunity in Systemic Lupus ErythematosusR01AR071703 · NIAMS · UNIVERSITY OF CHICAGO · PI Jill P Buyon, GEORGE Georgiou GEORGIOU · 2018 to 2026
$4.4MMolecular Control of Plasmacytoid Dendritic Cell Development and FunctionR01AI072571 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI REIZIS, BORIS · 2008 to 2017
$4.1MTranslational Basic and Clinical Research Training in RheumatologyT32AR069515 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jill P Buyon, Jose U. Scher · 2017 to 2026
$2.9MKinetic Characterization of Hematopoietic Stem Cell Differentiation During Homeostasis And Pathological ConditionsF32HL145997 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PUCELLA, JOSEPH NICHOLAS · 2019 to 2021
$176kBCL11A in normal B-cell biology and malignancyF32CA110624 · NCI · UNIVERSITY OF TEXAS AUSTIN · PI IPPOLITO, GREGORY C · 2005 to 2007
$156kDynamic Spatiotemporal Analysis of Immune Cells in the Tumor MicroenvironmentF32CA232666 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PEREZ, ORIANA · 2018 to 2020
$150kNCI NIH HHS F32 CA110624NCI NIH HHS F32 CA232666NCI NIH HHS T32 CA009161NHLBI NIH HHS F32 HL145997NIAID NIH HHS R01 AI072571NIAID NIH HHS R37 AI072571NIAID NIH HHS T32 AI100853NIAMS NIH HHS P50 AR070591NIAMS NIH HHS R01 AR071703NIAMS NIH HHS T32 AR069515
Abstract
Class-switched antibodies to double-stranded DNA (dsDNA) are prevalent and pathogenic in systemic lupus erythematosus (SLE), yet mechanisms of their development remain poorly understood. Humans and mice lacking secreted DNase DNASE1L3 develop rapid anti-dsDNA antibody responses and SLE-like disease. We report that anti-DNA responses in Dnase1l3
Indexed as
Cell CommunicationAnimalsAntibodies, AntinuclearAutoantigensAutoimmunityBiomarkersB-LymphocytesCD40 LigandDendritic CellsDisease Models, AnimalDisease SusceptibilityDNAEndodeoxyribonucleasesFluorescent Antibody TechniqueGerminal CenterInterferon Type IAntibodies, AntinuclearAutoantigensBiomarkersCD40 LigandDNADnase1l3 protein, mouseEndodeoxyribonucleasesInterferon Type IToll-Like Receptor 7Toll-Like Receptor 9anti-DNA antibodiesDNASE1L3extrafollicular B cell responseplasmacytoid dendritic cellssystemic lupus erythematosusTLR7TLR9type I interferon
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.